AN2 Therapeutics, Inc. ((ANTX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AN2 Therapeutics, Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998.’ The study aims to assess the safety and pharmacokinetics of AN2-502998, a new oral drug, in healthy volunteers, marking a significant step in its development.
The intervention involves administering AN2-502998, an experimental oral capsule, to participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) groups, with a placebo used for control.
This interventional study is randomized and double-blinded, meaning neither participants nor investigators know who receives the drug or placebo. The primary goal is basic science, focusing on understanding the drug’s effects.
The study began on May 31, 2025, and is currently recruiting participants. The last update was submitted on September 5, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.
This update could influence AN2 Therapeutics’ stock performance as investors monitor the trial’s progress and potential outcomes. Successful results could enhance investor confidence and position AN2-502998 favorably against competitors in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.